期刊文献+

参芎葡萄糖注射液单独应用与配合使用治疗慢性肾脏病的疗效比较 被引量:4

Curative effect comparison of ShenXiong glucose injection in the treatment of Chronic Kidney Disease-Compared Compound preparation with inoculation fluid applies and the coordinate use
下载PDF
导出
摘要 目的观察参芎葡萄糖注射液治疗慢性。肾脏病的临床疗效。方法将60例慢性肾脏病第三期的患者,随机分为①治疗组(30例),除给予常规治疗外,加用参芎葡萄糖注射液200ml,日一次静点;②对照组(30例),加用路路通注射液20 ml,日一次静点,4 w为一疗程。观察血尿素氮(BUN)和血清肌酐(SCr)的变化。结果治疗后两组各项检测指标均有不同程度好转,BUN和SCr均显著下降(P<0.01),但治疗组BUN和SCr降低程度明显高于对照组(P<0.05)。治疗组总有效率为83.3%,明显优于对照组60.0%(P<0.05)。结论参芎葡萄糖注射液能延缓慢性肾脏病的进展,配合使用明显优于单独应用。 Objective To evaluate the clinical efficacy of shenxiong glucose injection in the treatment of Chronic Kidney Disease(CKD). Methods 60 patients with CKD in the third intention were divided into a treatment ground (n = 30) and a controlled group ( n = 30). The treatment group received shenxiong glucose injection 100ml daily. 28 days for one course of treatment, the controlled group received Lulutong injection 20ml with 5% Glucose 150ml. The changes of serum BUN and SCr were observed. Results The serum BUN and SCr were significantly decreased in the two group after the treatment(P 〈 0. 01 )and the levels of BUN and SCr were significantly lower in the treatment group than those in the controlled group (P 〈 0.05 ). The total effective rates of the treatment group and controlled group were 83.3% and 60.0% respectively. There was a statistical difference between the two groups (P 〈 0. 05 ). Conclusion shenxiong glucose injection is effective in the treatment of the CKD, Compound preparation is better than Unilateral preparation.
出处 《环球中医药》 CAS 2009年第1期61-63,共3页 Global Traditional Chinese Medicine
关键词 参芎葡萄糖注射液 路路通注射液 慢性肾脏病 Shenxiong glucose injection Lulutong injection Panax Chronic kidney disease
  • 相关文献

参考文献4

二级参考文献14

  • 1刘明松,惠增环,赵景波,阎培泉,孔繁梅.慢性肺原性心脏病急性发作期64例加用川芎嗪治疗的疗效[J].新药与临床,1995,14(2):66-68. 被引量:12
  • 2石湘芸.高血压与内皮素的临床及实验研究[J].中华心血管病杂志,1994,22(2):126-126.
  • 3Alpers CE,Hudkins KL,Floege J,et al.Human renal cortical int erstitial ce ll with some features of smooth muscle cell participate in tubulointerstitial an d crescentic glomerular injury.Am J Soc Nephrol,1994,5:201-210.
  • 4Tsuyoshi S,Tetsuya K,Takuji S.Mizoribine improves renal tubulointerstit ial fibrosis in unilateral ureteral obstruction(UUO)-treated rat by inhibiting the infiltration of macrophages and the expression of α-smooth muscle actin.The Journal of Urology,1997,158:2316-2322.
  • 5Hewitson TD,Becker GJ.Interstitial in IgA glomerulonephritis.Am J Nephr ol,1995,15:111-117.
  • 6Diamond JR,Van Goor H,Ding G,et al. Myofibroblasts in experimental hydr onephrosis.Am J Pathol,1995,146:121-129.
  • 7Hewitson TD,Wu H,Becker GJ.Instertitial Myofibroblasts in experimental renal infection and scarring.Am J Nephrol,1995,15:411-417.
  • 8王玉良 巴彦坤.川芎嗪对心血管组织的药物和电生理作用——一种新的"钙拮抗剂"[J].中西医结合杂志,1985,5(5):291-291.
  • 9MAK IT,WEGLICKI WB.Protection by β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation [J].Circ Res,1988,63(1): 262.
  • 10MAK IT,WEGLICKI WB.Comparative antioxidant activities of propreanolol,nifedipine,verapamil,and diltiazem sarcolemmal membrane lipid peroxidation [J].Circ Res,1990,66(5): 1449-1452.

共引文献96

同被引文献51

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部